Oncology Consortium

Impactful Education Through Innovative Engagement

roy.berger@theoncologyconsortium.com | (516) 729-0303

Tanios Bekaii-Saab, MD

Gastrointestinal Oncology Consortium

Tanios Bekaii-Saab, MD joined the faculty at The Ohio State University - Arthur G. James Cancer Hospital and Solove Research Institute in 2002 where he is a tenured Associate Professor of Medicine and Pharmacology and section chief for the gastrointestinal cancer program. He is also the chairman of the disease specific research group for the comprehensive cancer center. Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon, followed by residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts.

Charles S. Fuchs, MD, MPH

Gastrointestinal Oncology Consortium

Charles S. Fuchs, MD, MPH, is Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer. He leads the Dana-Farber/Harvard Cancer Center Gastrointestinal Malignancies Program and the DF/HCC SPORE Grant in Gastrointestinal Cancers.

Axel Grothey, MD

Gastrointestinal Oncology Consortium

Axel Grothey, M.D., is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic. He holds the academic rank of professor of oncology and has teaching/examining privileges in Clinical & Translational Science at Mayo Graduate School. He is a member of Mayo Clinic’s Cancer Center.

Aiwa Ruth He, MD, PhD

Gastrointestinal Oncology Consortium

Dr. He is a GI Oncologist and Associate Professor at Lombardi Comprehensive Cancer Center, Georgetown University. The research focus of her laboratory is on the deregulation of signaling transduction pathways in carcinogenesis; and her expertise is in designing and implementing investigator initiated clinical studies.

Heinz-Josef Lenz, MD, FACP

Gastrointestinal Oncology Consortium

Dr. Lenz is Professor of Medicine and Professor of Preventive Medicine; Kathryn Balakrishnan Chair for Cancer Research; Associate Director, Clinical Research; Co-Chair of GI Oncology; and Co-Director USC Center for Molecular Pathways and Drug Discover at the University of Southern California Keck School of Medicine and USC/Norris Comprehensive Cancer.

John L. Marshall, MD

Gastrointestinal Oncology Consortium

Chief, Hematology and Oncology Lombardi Comprehensive Cancer Center Georgetown University. An internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials. Established the Otto J Ruesch Center for the Cure of GI Cancers.

Michael Morse, MD, FACP

Gastrointestinal Oncology Consortium

Professor of Medicine in the Division of Medical Oncology at Duke University Medical Center, Durham, NC. Clinical expertise includes management of gastrointestinal malignancies and melanoma and his research expertise includes the development of targeted therapies including immunotherapies for cancer. He has published extensively and a national speaker on topics in cancer immunotherapy, targeted therapies, and gastrointestinal malignancies, including textbooks on Cancer Vaccines and Liver Tumors.

Weijing Sun, MD, FACP

Gastrointestinal Oncology Consortium

Weijing Sun, MD is Professor of Medicine, Director of GI Cancer of the Hematology-Oncology Division, and Co-Director of UPMC Gastrointestinal Cancer Center of Excellence at the University of Pittsburgh Cancer Institute. His focus is on the treatment and clinical research of GI malignances, mainly on the development of new drugs and biologic/targeted oriented agents in treatment/therapy (including translational research) of gastrointestinal malignances with great experience in the early phase clinical trials (phase I, II) by designing, developing and conducting clinical trials, many of which have been published.

Eugene A. Woltering, MD, FACS

Gastrointestinal Oncology Consortium

Eugene A. Woltering, MD, FACS, is the James D. Rives Professor of Surgery and Neurosciences at the Louisiana State University Health Sciences Center in New Orleans. He also is the Section Chief of Surgical Endocrinology and the Director of Surgical Research at this institution. Dr. Woltering attended medical school at Ohio State University School of Medicine and completed his surgical residency at Vanderbilt University Affiliated Hospitals in Nashville, Tennessee. He has also completed fellowships in surgical oncology at The Ohio State University School of Medicine and the National Cancer Institute. Dr. Woltering specializes in the diagnosis and management of neuroendocrine tumors of the gastro-entero-pancreatic tract. His research interests include the development of radioactive drugs for the diagnosis and therapy of tumors and the development of human tissue based models that can be used to predict drug activity in patients.

Download Capability Slide

Oncology Consortium | All Rights Reserved 2012-2017
Back to Top